Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Pliant Therapeutics, Inc. PLRX stock is trading lower on Monday.On Friday, during after-hours trading, Pliant Therapeutics announced it has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and stiffening of the lung tissue. Patients currently enrolled in BEACON-IPF will remain in the trial.The move follows a prespecified data review and recommendations by the tria ...